The featured speakers will share practical case studies of AI applications in antibody discovery. TORONTO, Jan. 30, 2025 /PRNewswire-PRWeb/ -- This webinar will explore how AI is revolutionizing ...

In this webinar, brought to you by The Antibody Society (MA ... then held a post doc position at King’s College London in Prof. Karagiannis’ Cancer Antibody Discovery & Immunotherapy Group, where she ...

SAB-142 was generally well-tolerated among healthy volunteers; data from Phase 1 trial confirms SAB-142 does not cause serum sickness or ...

The rise of novel monoclonal antibody (mAb) formats has not only transformed the ... specialized approaches to maintain efficiency and product integrity. In this webinar, experienced panelists discuss ...

SAB-142 was generally well-tolerated among healthy volunteers; data from Phase 1 trial confirms SAB-142 does not cause serum sickness or anti-drug antibodies at target dose Study results support that ...

Evaluate’s latest analysis forecasts an $82 billion increase in major product revenues in 2025 – the largest annual growth ...

Using advanced genetic engineering and antibody science to develop Transchromosomic (Tc ... our expected cash runway and the development and efficacy of our T1D program and other discovery programs.

Olatec Therapeutics, Inc., a leader in the developing class of selective NLRP3 inhibitors, today announced that long-time collaborator and advisor, Prof. Dr. Marc Donath, has joined the Company's ...